Our research program is aimed at understanding the genetic program that underlies the pathogenesis of glioblastoma, the most prevalent and malignant form of brain cancer. Applying a combination of cell/molecular biology, oncogenomic, and mouse engineering approaches, we systematically characterize novel glioma-relevant oncogenes and tumor suppressors with important roles in glioma cell survival and metabolism. In addition, my laboratory seeks to understand fundamental mechanisms of tumor-mediated immune suppression and to develop novel nanotechnology-enabled approaches directed against actionable immune targets. My group is known for its bench-to-beside efforts to drive nanotechnologies toward clinical opportunity. These efforts have resulted in the first in-human clinical trial of gene-regulatory spherical nucleic acids (SNAs) for the treatment of recurrent glioblastoma.

• Lab Website

The Stegh Lab welcomes all regardless of physical ability designation, gender, sexual orientation, age, race/ethnicity, religion, cultural background, or socioeconomic status. We are a team of scientist with diverse backgrounds and experiences, who have created a nurturing and inclusive environment that promotes a sense of belonging. As a team of scientists with the common goal to fight against brain cancer, we speak out against racism, intolerance, and biases, and promise to continuously broaden our perspective on social injustice within academia and beyond, communicate with each other to better understand a lab member’s individual challenges, and learn from each other through open dialogue.